Braden Michael Leonard Purchases 29,600 Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Stock

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Get Free Report) major shareholder Braden Michael Leonard acquired 29,600 shares of the business's stock in a transaction on Tuesday, September 24th. The shares were bought at an average cost of $1.41 per share, with a total value of $41,736.00. Following the completion of the acquisition, the insider now owns 3,388,649 shares in the company, valued at $4,777,995.09. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Braden Michael Leonard also recently made the following trade(s):

• On Tuesday, September 17th, Braden Michael Leonard purchased 55,300 shares of Reneo Pharmaceuticals stock. The shares were purchased at an average price of $1.36 per share, with a total value of $75,208.00.
• On Tuesday, August 13th, Braden Michael Leonard purchased 171,339 shares of Reneo Pharmaceuticals stock. The stock was acquired at an average price of $1.39 per share, for a total transaction of $238,161.21.

Reneo Pharmaceuticals Stock Performance

Shares of NASDAQ:RPHM traded up $0.09 on Thursday, reaching $1.62. The company's stock had a trading volume of 560,547 shares, compared to its average volume of 249,533. The company has a 50-day simple moving average of $1.46 and a 200 day simple moving average of $1.59. Reneo Pharmaceuticals, Inc. has a 52-week low of $0.98 and a 52-week high of $9.21. The company has a market cap of $54.14 million, a P/E ratio of -0.74 and a beta of 0.19.

Reneo Pharmaceuticals (NASDAQ:RPHM - Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.01. On average, equities research analysts forecast that Reneo Pharmaceuticals, Inc. will post -0.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Jump Financial LLC purchased a new position in Reneo Pharmaceuticals in the 4th quarter worth about $41,000. Vestal Point Capital LP bought a new stake in shares of Reneo Pharmaceuticals in the 4th quarter valued at about $640,000. Pale Fire Capital SE lifted its position in shares of Reneo Pharmaceuticals by 102.7% in the 4th quarter. Pale Fire Capital SE now owns 30,100 shares of the company's stock worth $48,000 after purchasing an additional 15,249 shares during the period. Marquette Asset Management LLC bought a new position in shares of Reneo Pharmaceuticals during the first quarter valued at approximately $122,000. Finally, Highbridge Capital Management LLC lifted its holdings in Reneo Pharmaceuticals by 6.5% during the second quarter. Highbridge Capital Management LLC now owns 2,915,376 shares of the company's stock worth $4,402,000 after buying an additional 178,806 shares during the period. Institutional investors own 90.98% of the company's stock.

Reneo Pharmaceuticals Company Profile

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.